Boys and girls, I've still got a boatload of shares underwater, but i'm holding tight. It boils down to whether or not AV 203 is a viable drug. There are other similar drugs that are progressing in the pipelines of bigger/better companies- but its 2 or 3 not 8 like tivozanib. If the drug works (tivozanib does- its just not significantly better than the 7 others when compared to the effect of combining treatments versus placebos) If its a viable drug- this company is worth $15 to $20/share, if it not close to nothing, but its close to nothing today. Drugs have a 50% fall out so its better than a 15:1 longshot horse, and I'd buy at this price if I didn't have too much in already, but its going to be about convincing Biogen that bought into a winner.